News
Median Technologies Reschedules Its Corporate Update Webcasts on May 4, 2023
Regulatory News:
Median Technologies (ALMDT:PA) announced today that the two webcasts during which Fredrik Brag, CEO and Founder will provide a corporate update, are rescheduled from May 3rd to
Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces that the Company’s
Median Technologies Reports Full-year 2022 Results and Business Indicators for the First Quarter Of 2023
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) (Paris;ALMDT) whose Board of Directors met on April 19, 2023 to approve the consolidated financial statements for the financial
Sensorion to participate in Chardan’s Annual Genetic Medicines & Cell Therapy Manufacturing Summit and Kempen’s Life Sciences Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, is pleased to announce its participation
MYHOTELMATCH: Approval of the resolutions by the General Meeting of 4 April 2023
BILENDI: 2022 results: Strong increase in profitability
Sensorion Reports Full-Year 2022 Financial Results and Business Update
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces today its full-year 2022
Valbiotis veröffentlicht seine Jahresergebnisse 2022 und gibt ein Update zu seiner strategischen Roadmap
Valbiotis (FR0013254851 – ALVAL, PEA / SME förderungswürdig (Paris: ALVAL), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Valbiotis Publishes Its 2022 Annual Results and Provides an Update on Its Strategic Roadmap
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and
Sensorion Announces Agenda For R&D Day Showcasing Gene Therapy For Inner Ear Disease
Regulatory News:
Sensorion, (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the
Valbiotis gibt den letzten Besuch des letzten Patienten in der Phase II/III REVERSE-IT Studie zu TOTUM•63 in Partnerschaft mit Nestlé Health Science bekannt
Valbiotis (FR0013254851 - ALVAL, PEA / SME förderungswürdig (Paris:ALVAL), ein kommerziell orientiertes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur
Sensorion Discloses No Exposure To Silicon Valley Bank Closure
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, has learned that Silicon Valley Bank (SVB) has
Valbiotis Announces the Last Visit of the Last Patient in the Phase II/III REVERSE-IT Study on TOTUM•63, in Partnership with Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing
GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion to Participate in the 6th Annual Bioprocessing Summit Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its
ROCTOOL: Freudenberg e-Power Systems sign a strategic agreement with Roctool for new Fuel Cell applications
Median Technologies to present new and breakthrough results for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device at the European Congress of Radiology, taking place March 1-5 2023 in Vienna, Austria
Regulatory News:
Median Technologies (ALMDT:PA) today announces new and breakthrough results for its iBiopsy® Lung Cancer Screening (LCS) AI/ML tech-based CADe/CADx1 Software as Medical Device
Median Technologies Announces Completion of the Q-Submission Phase with the FDA for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device
Regulatory News:
Median Technologies (ALMDT) (Paris:ALMDT) announces today that the Company has received feedback from the United States Food and Drug Administration (FDA) regarding the
Sensorion Further Strengthens Leadership, Appoints David Lawrence as Chief Financial Officer
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Valbiotis veröffentlicht Brief an die Aktionäre und Finanzkommunikationskalender für 2023
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA / KMU-qualifiziert), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich auf wissenschaftliche Innovationen
Valbiotis Publishes Its Letter to Shareholders and Its 2023 Financial Calendar
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible), a commercially oriented Research and Development company committed to scientific innovation for preventing and combating
Median Technologies to Participate in the Cowen’s 43rd Annual Health Care Conference
Regulatory News:
Median Technologies (Paris:ALMDT), will be participating in the Cowen’s 43rd Annual Health Care Conference, taking place on March 6 – 8 ,2023, at the Boston Marriott Copley Place
BILENDI: 2022 : record revenues of €61.5 million (+39.5%)
Sensorion announces R&D Day focusing on its Gene Therapy programs
Regulatory News:
Sensorion, (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and